Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792078 | 0.83 | HTR1A (0.50) | HTR1AMAPTDRD2HTR2AHTR2C | |
| SCHEMBL5233991 | 0.82 | HTR1A (0.54) | HTR1AMAPTDRD2HTR2AHTR2C | |
| SCHEMBL7828214 | 0.82 | MAPT (0.70) | HTR1AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL6319964 | 0.81 | MAPT (0.51) | HTR1AMAPTDRD2HTR2AHTR2C | |
| SCHEMBL5957060 | 0.80 | MAPT (0.51) | HTR1AMAPTDRD2HTR2AHTR2C | |
| SCHEMBL5233437 | 0.79 | HTR1A (0.54) | HTR1AMAPTDRD2HTR2AHTR2C | |
| SCHEMBL7817707 | 0.79 | MAPT (0.68) | HTR1AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL7826778 | 0.78 | MAPT (0.59) | HTR1AMAPTDRD2SMN1; SMN2MEN1 | |
| SCHEMBL5240201 | 0.76 | HTR1A (0.65) | HTR1A | |
| SCHEMBL5232473 | 0.76 | HTR1A (0.65) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800641-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | claimed |
| WO-2002088133-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-2,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6800641-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088133-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-2,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183331-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-2,3-diaza-cyclopenta[a]naphthalene | SNCA, SYNJ1, SLC6A3 | HTR1A 86/4885MAPT 91/4885DRD2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.